Document:

NEURO-HITECH,
      INC.

    

    REGISTRATION
      RIGHTS AGREEMENT

    

    NOVEMBER
      29, 2006

    
      
        
        

      

      
        
        

        
          

        

      

       

    

    

    TABLE
      OF
      CONTENTS

    

    
      	
              1.

            	
              Registration
                Rights

            	
              1

            
	 	
              1.1

            	
              Definitions

            	
              1

            
	 	
              1.2

            	
              Company
                Registration

            	
              3

            
	 	
              1.3

            	
              Obligations
                Of The Company

            	
              4

            
	 	
              1.4

            	
              Furnish
                Information

            	
              5

            
	 	
              1.5

            	
              Delay
                Of Registration

            	
              5

            
	 	
              1.6

            	
              Indemnification

            	
              5

            
	 	
              1.7

            	
              Reports
                Uner Securities Exchange Act

            	
              7

            
	 	
              1.8

            	
              Transfer
                Or Assignment Of Registration Rights

            	
              7

            
	 	
              1.9

            	
              “Market
                Stand-Off” Agreement

            	
              8

            
	 	 	 	 
	
              2.

            	
              Covenants
                Of The Company To The Investors

            	
              9

            
	 	
              2.1

            	
              Information
                Rights

            	
              9

            
	 	
              2.2

            	
              Confidentiality

            	
              9

            
	 	 	 	 
	
              3.

            	
              Legend

            	
              10

            
	 	 	 
	
              4.

            	
              Miscellaneous

            	
              10

            
	 	
              4.1

            	
              Governing
                Law

            	
              10

            
	 	
              4.2

            	
              Waivers
                And Amendments

            	
              10

            
	 	
              4.3

            	
              Successors
                And Assigns

            	
              10

            
	 	
              4.4

            	
              Entire
                Agreement

            	
              10

            
	 	
              4.5

            	
              Notices

            	
              11

            
	 	
              4.6

            	
              Interpretation

            	
              11

            
	 	
              4.7

            	
              Severability

            	
              11

            
	 	
              4.8

            	
              Counterparts

            	
              11

            
	 	
              4.9

            	
              Telecopy
                Execution And Delivery

            	
              11

            
	 	
              4.10

            	
              Warrant
                Exercise

            	
              11

            

    

     

    
      
        
        

      

      
        i

        
          

        

      

       

    

    

    REGISTRATION
      RIGHTS AGREEMENT

    

    THIS
      REGISTRATION RIGHTS AGREEMENT (this “AGREEMENT”) is made as of November 29,
      2006, between Neuro-Hitech, Inc., a Delaware corporation (the “COMPANY”), and
      the individuals and entities listed on Schedule A hereto (each, an “INVESTOR”
and collectively, the “INVESTORS”). 

    

    RECITALS

    

    WHEREAS,
      the Company and the Investors are parties to the Securities Purchase Agreement
      dated November 16, 2006 (the “PURCHASE AGREEMENT”); 

    

    WHEREAS,
      the Investors’ obligations under the Purchase Agreement are conditioned upon
      certain registration rights under the Securities Act of 1933, as amended (the
      “SECURITIES ACT”); and 

    

    WHEREAS,
      the Investors and the Company desire to provide for the rights of registration
      under the Securities Act as are provided herein upon the execution and delivery
      of this Agreement by such investors and the Company. 

    

    NOW,
      THEREFORE, in consideration of the promises, covenants, and conditions set
      forth
      herein, the parties hereto hereby agree as follows: 

    

    1.  REGISTRATION
      RIGHTS. 

    

    1.1  DEFINITIONS.
      As used in this Agreement, the following terms shall have the meanings set
      forth
      below: 

    

    (a) “ADDITIONAL
      FINANCING” means the sale by the Company, in one or more closings, of securities
      raising proceeds equal to (x) $9.3 million less (y) the amount of proceeds
      raised at the closing under the Purchase Agreement. 

    

    (b) “COMMISSION”
      means the United States Securities and Exchange Commission. 

    

    (c) “COMMON
      STOCK” means the Company’s common stock, par value $0.001 per share.

    

    (d) “CONVERSION
      STOCK” means the shares of Common Stock issued or issuable upon exercise of the
      Warrants to purchase Common Stock issued pursuant to the Purchase Agreement.
      

    

    (e) “EFFECTIVENESS
      DATE” means the 120th day following the Filing Date. 

    
      
        
        

      

      
        
        

        
          

        

      

       

    

     

    (f) “EFFECTIVENESS
      PERIOD” means the period beginning on the date of effectiveness of the
      Registration Statement and ending on the earlier of when (i) all Registrable
      Securities have been sold or (ii) all Registrable Securities may be sold
      immediately without registration under the Securities Act and without volume
      restrictions pursuant to Rule 144(k), as determined by the counsel to the
      Company pursuant to a written opinion letter to such effect, addressed and
      reasonably acceptable to the Company’s transfer agent and the affected
      Investors.

    

    (g) “EXCHANGE
      ACT” means the Securities Exchange Act of 1934, as amended. 

    

    (h) “FAIR
      MARKET VALUE” means the average of the high and low prices of publicly traded
      shares of Common Stock, rounded to the nearest cent, on the principal national
      securities exchange on which shares of Common Stock are listed (if the shares
      of
      Common Stock are so listed), or on the Nasdaq Stock Market (if the shares of
      Stock are regularly quoted on the Nasdaq Stock Market), or, if not so listed
      or
      regularly quoted, the mean between the closing bid and asked prices of publicly
      traded shares of Common Stock in the over-the-counter market, or, if such bid
      and asked prices shall not be available, as reported by any nationally
      recognized quotation service selected by the Company, or as determined by the
      Board of Directors in a manner consistent with the provisions of the Internal
      Revenue Code, as amended. 

    

    (i) “FILING
      DATE” means, with respect to the Registration Statement required to be filed
      hereunder, the earlier of (a) 60 days after the closing under the Purchase
      Agreement or (b) two business days following the final closing pursuant to
      the
      Additional Financing. 

    

    (j) “INVESTOR”
      means any person owning Registrable Securities. 

    

    (k) The
      terms
“REGISTER,” “REGISTERED” and “REGISTRATION” refer to a registration effected by
      preparing and filing a registration statement or similar document in compliance
      with the Securities Act, and the declaration or ordering of effectiveness of
      such registration statement or document. 

    

    (l) “REGISTRABLE
      SECURITIES” means (i) the Shares, (ii) the Conversion Stock and (iii) any shares
      issued or issuable upon the conversion or exercise of any warrant, right or
      other security that is issued as, or a dividend or other distribution with
      respect to, or in exchange for, or in replacement of, the shares referenced
      in
      (i) and (ii) above; PROVIDED, HOWEVER, that Registrable Securities shall not
      include any shares of Common Stock which have previously been registered or
      which have been sold to the public either pursuant to a registration statement
      or Rule 144, or which have been sold in a private transaction in which the
      transferor’s rights under this Section 1 are not assigned. 

    

    (m) “REGISTRATION
      STATEMENT” means the registration statement filed with the Commission pursuant
      to Section 1.2(a) of this Agreement.

    
      
        
        

      

      
        2

        
          

        

      

       

    

    

    (n) “RULE
      144” means Rule 144 as promulgated by the Commission under the Securities Act,
      as such Rule may be amended from time to time, or any similar successor rule
      that may be promulgated by the Commission. 

    

    (o) “RULE
      145” means Rule 145 as promulgated by the Commission under the Securities Act,
      as such Rule may be amended from time to time, or any similar successor rule
      that may be promulgated by the Commission. 

    

    (p) “SHARES”
      means the shares of the Common Stock issued pursuant to the Purchase Agreement.
      

    

    (q) “WARRANTS”
      means the warrants to purchase Common Stock issued pursuant to the Purchase
      Agreement. 

    

    1.2  COMPANY
      REGISTRATION. 

     

    (a) On
      or
      prior to the Filing Date, the Company shall prepare and file with the Commission
      a registration statement covering the Registrable Securities for an offering
      to
      be made on a continuous basis pursuant to Rule 415. The Registration Statement
      shall be on Form SB-2 or Form S-3 (except if the Company is not then eligible
      to
      register for resale the Registrable Securities on Form SB-2 or Form S-3, in
      which case such registration shall be on another appropriate form in accordance
      herewith). The Company shall cause the Registration Statement to become
      effective and remain effective as provided herein. The Company shall use its
      reasonable commercial efforts to cause the Registration Statement to be declared
      effective under the Securities Act as promptly as possible after the filing
      thereof, but in any event no later than the Effectiveness Date. The Company
      shall use its reasonable commercial efforts to keep the Registration Statement
      continuously effective under the Securities Act during the Effectiveness Period.
      

    

    (b) If:
      (i)
      the Registration Statement is not filed on or prior to the Filing Date; (ii)
      the
      Registration Statement is not declared effective by the Commission by the
      Effectiveness Date; or (iii) after the Registration Statement is filed with
      and
      declared effective by the Commission, the Registration Statement ceases to
      be
      effective (by suspension or otherwise) as to all Registrable Securities to
      which
      it is required to relate at any time prior to the expiration of the
      Effectiveness Period (without being succeeded immediately by an additional
      registration statement filed and declared effective) for a period of time which
      shall exceed 30 days in the aggregate per year or more than 20 consecutive
      calendar days (defined as a period of 365 days commencing on the date the
      Registration Statement is declared effective); (any such failure or breach being
      referred to as an “Event,” and for purposes of clause (i) or (ii) the date on
      which such Event occurs, or for purposes of clause (iii) the date which such
      30
      day or 20 consecutive day period (as the case may be) is exceeded, or for
      purposes of clause (iv) the date on which such three (3) Trading Day period
      is
      exceeded, being referred to as “Event Date”), then until the applicable Event is
      cured, the Company shall pay to each Investor in Common Stock at Fair Market
      Value, as liquidated damages and not as a penalty, equal to 1.0%, for each
      thirty (30) day period (prorated for partial periods), calculated on a daily
      basis, up to a maximum of 6%, of the aggregate amount invested by such Investor.
      While such Event continues, such liquidated damages shall be paid not less
      often
      than each thirty (30) days. Any unpaid liquidated damages as of the date when
      an
      Event has been cured by the Company shall be paid within three (3) days
      following the date on which such Event has been cured by the Company.

    
      
        
        

      

      
        3

        
          

        

      

       

    

    

    (c) The
      Company shall bear and pay all expenses incurred in connection with any
      registration, filing or qualification of Registrable Securities with respect
      to
      the registrations pursuant to this Section 1.2 for each Investor, including
      (without limitation) all registration, filing and qualification fees, printer’s
      fees, accounting fees and fees and disbursements of counsel for the Company,
      but
      excluding underwriting discounts and commissions relating to Registrable
      Securities and fees and disbursements of counsel for the Investors.

    

    1.3  OBLIGATIONS
      OF THE COMPANY. Whenever required under this Section 1 to effect the
      registration of any Registrable Securities, the Company shall, as expeditiously
      as reasonably possible: 

     

    (a) Prepare
      and file with the Commission a registration statement with respect to such
      Registrable Securities and use its commercially reasonable efforts to cause
      such
      registration statement to become effective, and, upon the request of the
      Investors of at least a majority of the Registrable Securities registered
      thereunder, keep such Registration Statement effective during the Effectiveness
      Period; 

    

    (b) Prepare
      and file with the Commission such amendments and supplements to such
      Registration Statement and the prospectus used in connection with such
      Registration Statement as may be necessary to comply with the provisions of
      the
      Securities Act with respect to the disposition of all securities covered by
      such
      Registration Statement; 

    

    (c) Furnish
      to the Investors such numbers of copies of a prospectus, including a preliminary
      prospectus, in conformity with the requirements of the Securities Act, and
      such
      other documents as they may reasonably request in order to facilitate the
      disposition of Registrable Securities owned by them (provided that the Company
      would not be required to print such prospectuses if readily available to
      Investors from any electronic service, such as on the EDGAR filing database
      maintained at www.sec.gov); 

    

    (d) Use
      its
      commercially reasonable efforts to register and qualify the securities covered
      by such Registration Statement under such other securities’ or blue sky laws of
      such jurisdictions as shall be reasonably requested by the Investors; provided
      that the Company shall not be required in connection therewith or as a condition
      thereto to qualify to do business or to file a general consent to service of
      process in any such states or jurisdictions; 

    

    (e) In
      the
      event of any underwritten public offering, enter into and perform its
      obligations under an underwriting agreement, in usual and customary form, with
      the managing underwriter(s) of such offering (each Investor participating in
      such underwriting shall also enter into and perform its obligations under such
      an agreement); 

    

    (f) Notify
      each Investor of Registrable Securities covered by such Registration Statement
      at any time when a prospectus relating thereto is required to be delivered
      under
      the Securities Act of the happening of any event as a result of which the
      prospectus included in such Registration Statement, as then in effect, includes
      an untrue statement of a material fact or omits to state a material fact
      required to be stated therein or necessary to make the statements therein not
      misleading in the light of the circumstances then existing; 

    
      
        
        

      

      
        4

        
          

        

      

       

    

    

    (g) Cause
      all
      such Registrable Securities registered pursuant hereunder to be listed on each
      securities exchange or nationally recognized quotation system on which similar
      securities issued by the Company are then listed; and 

    

    (h) Provide
      a
      transfer agent and registrar for all Registrable Securities registered pursuant
      hereunder and a CUSIP number for all such Registrable Securities, in each case
      not later than the effective date of such registration. 

    

    1.4  FURNISH
      INFORMATION. It shall be a condition precedent to the Company’s obligations to
      take any action pursuant to this Section 1 with respect to the Registrable
      Securities of any selling Investor that such Investor shall furnish to the
      Company such information regarding such Investor, the Registrable Securities
      held by such Investor, and the intended method of disposition of such securities
      as shall be required by the Company or the managing underwriters, if any, to
      effect the registration of such Investor’s Registrable Securities. 

     

    

    1.5  DELAY
      OF
      REGISTRATION. No Investor shall have any right to obtain or seek an injunction
      restraining or otherwise delaying any such registration as the result of any
      controversy that might arise with respect to the interpretation or
      implementation of this Section 1. 

     

    1.6  INDEMNIFICATION.
      

     

    (a) To
      the
      extent permitted by law, the Company will indemnify and hold harmless each
      Investor, any underwriter (as defined in the Securities Act) for such Investor
      and each person, if any, who controls such Investor or underwriter within the
      meaning of the Securities Act or the Exchange Act, against any losses, claims,
      damages, or liabilities (joint or several) to which any of the foregoing persons
      may become subject under the Securities Act, the Exchange Act or other federal
      or state securities law, insofar as such losses, claims, damages or liabilities
      (or actions in respect thereof) arise out of or are based upon any of the
      following statements, omissions or violations (collectively, a “VIOLATION”): (i)
      any untrue statement or alleged untrue statement of a material fact contained
      in
      the Registration Statement, including any preliminary prospectus or final
      prospectus contained therein or any amendments or supplements thereto
      (collectively, the “FILINGS”), (ii) the omission or alleged omission to state in
      the Filings a material fact required to be stated therein, or necessary to
      make
      the statements therein not misleading, or (iii) any violation or alleged
      violation by the Company of the Securities Act, the Exchange Act, any state
      securities law or any rule or regulation promulgated under the Securities Act,
      the Exchange Act or any state securities law; and the Company will pay any
      legal
      or other expenses reasonably incurred by any person to be indemnified pursuant
      to this Section 1.6(a) in connection with investigating or defending any such
      loss, claim, damage, liability or action; PROVIDED, HOWEVER, that the indemnity
      agreement contained in this Section 1.6(a) shall not apply to amounts paid
      in
      settlement of any such loss, claim, damage, liability, or action if such
      settlement is effected without the consent of the Company (which consent shall
      not be unreasonably withheld), nor shall the Company be liable in any such
      case
      for any such loss, claim, damage, liability, or action to the extent that it
      arises out of or is based upon a Violation that occurs in reliance upon and
      in
      conformity with written information furnished expressly for use in connection
      with such registration by any such Investor, underwriter or controlling person.
      

    
      
        
        

      

      
        5

        
          

        

      

       

    

    

    (b) To
      the
      extent permitted by law, each Investor will indemnify and hold harmless the
      Company, each of its directors, each of its officers who has signed the
      Registration Statement, each person, if any, who controls the Company within
      the
      meaning of the Securities Act, any underwriter, any other Investor selling
      securities in such Registration Statement and any controlling person of any
      such
      underwriter or other Investor, against any losses, claims, damages, or
      liabilities (joint or several) to which any of the foregoing persons may become
      subject under the Securities Act, the Exchange Act or other federal or state
      securities law insofar as such losses, claims, damages or liabilities (or
      actions in respect thereto) arise out of or are based upon any Violation, in
      each case to the extent (and only to the extent) that such Violation occurs
      in
      reliance upon and in conformity with written information furnished by such
      Investor expressly for use in connection with such registration; and each such
      Investor will pay any legal or other expenses reasonably incurred by any person
      to be indemnified pursuant to this Section 1.6(b) in connection with
      investigating or defending any such loss, claim, damage, liability or action;
      PROVIDED, HOWEVER, that the indemnity agreement contained in this Section 1.6(b)
      shall not apply to amounts paid in settlement of any such loss, claim, damage,
      liability or action if such settlement is effected without the consent of the
      Investor (which consent shall not be unreasonably withheld); PROVIDED, HOWEVER,
      in no event shall any indemnity under this subsection 1.6(b) exceed the gross
      proceeds from the offering received by such Investor. 

    

    (c) Promptly
      after receipt by an indemnified party under this Section 1.6 of notice of the
      commencement of any action (including any governmental action), such indemnified
      party will, if a claim in respect thereof is to be made against any indemnifying
      party under this Section 1.6, deliver to the indemnifying party a written notice
      of the commencement thereof and the indemnifying party shall have the right
      to
      participate in, and, to the extent the indemnifying party so desires, jointly
      with any other indemnifying party similarly noticed, to assume the defense
      thereof with counsel mutually satisfactory to the parties; PROVIDED, HOWEVER,
      that an indemnified party (together with all other indemnified parties that
      may
      be represented without conflict by one counsel) shall have the right to retain
      one separate counsel, with the fees and expenses to be paid by the indemnifying
      party, if representation of such indemnified party by the counsel retained
      by
      the indemnifying party would be inappropriate due to actual or potential
      differing interests between such indemnified party and any other party
      represented by such counsel in such proceeding. The failure to deliver written
      notice to the indemnifying party within a reasonable time of the commencement
      of
      any such action, if materially prejudicial to its ability to defend such action,
      shall relieve such indemnifying party of any liability to the indemnified party
      under this Section 1.6, but the omission so to deliver written notice to the
      indemnifying party will not relieve it of any liability that it may have to
      any
      indemnified party otherwise than under this Section 1.6. 

    

    (d) If
      the
      indemnification provided for in Sections 1.6(a) and (b) is held by a court
      of
      competent jurisdiction to be unavailable to an indemnified party with respect
      to
      any loss, claim, damage or expense referred to therein, then the indemnifying
      party in lieu of indemnifying such indemnified party hereunder, shall contribute
      to the amount paid or payable by such indemnified party as a result of such
      loss, claim, damage or expense in such proportion as is appropriate to reflect
      the relative fault of the indemnifying party on the one hand and of the
      indemnified party on the other in connection with the statements or omissions
      or
      alleged statements or omissions that resulted in such loss, liability, claim
      or
      expense as well as any other relevant equitable considerations. The relative
      fault of the indemnifying party and of the indemnified party shall be determined
      by reference to, among other things, whether the untrue or alleged untrue
      statement of a material fact relates to information supplied by the indemnifying
      party or by the indemnified party and the parties’ relative intent, knowledge,
      access to information and opportunity to correct or prevent such statement
      or
      omission. In no event shall any Investor be required to contribute an amount
      in
      excess of the gross proceeds from the offering received by such Investor.

    
      
        
        

      

      
        6

        
          

        

      

       

    

    

    (e) Notwithstanding
      the foregoing, to the extent that the provisions on indemnification and
      contribution contained in the underwriting agreement entered into in connection
      with the underwritten public offering are in conflict with the foregoing
      provisions, the provisions of the underwriting agreement shall control.

    

    (f) The
      obligations of the Company and Investors under this Section 1.6 shall survive
      the completion of any offering of Registrable Securities in the Registration
      Statement under this Section 1, and otherwise. 

    

    1.7  REPORTS
      UNDER SECURITIES EXCHANGE ACT. With a view to making available the benefits
      of
      certain rules and regulations of the Commission, including Rule 144, that may
      at
      any time permit an Investor to sell securities of the Company to the public
      without registration or pursuant to a registration on Form SB-2, the Company
      agrees to: 

     

    (a) make
      and
      keep public information available, as those terms are understood and defined
      in
      Rule 144; 

    

    (b) take
      such
      action as is necessary to enable the Investors to utilize Form SB-2 for the
      sale
      of their Registrable Securities; 

    

    (c) file
      with
      the Commission in a timely manner all reports and other documents required
      of
      the Company under the Securities Act and the Exchange Act; and 

    

    (d) furnish
      to any Investor, so long as the Investor owns any Registrable Securities,
      forthwith upon request (i) a written statement by the Company that it has
      complied with the reporting requirements of Rule 144, the Securities Act and
      the
      Exchange Act, or that it qualifies as a registrant whose securities may be
      resold pursuant to Form SB-2, (ii) a copy of the most recent annual or quarterly
      report of the Company and such other reports and documents so filed by the
      Company, and (iii) such other information as may be reasonably requested in
      availing any Investor of any rule or regulation of the Commission that permits
      the selling of any such securities without registration or pursuant to such
      form. 

    

    1.8  TRANSFER
      OR ASSIGNMENT OF REGISTRATION RIGHTS. The rights to cause the Company to
      register Registrable Securities pursuant to this Section 1 may be transferred
      or
      assigned, but only with all related obligations, by an Investor (a) to a
      transferee or assignee who acquires at least 50,000 shares (subject to
      appropriate adjustment for stock splits, stock dividends and combinations)
      of
      Registrable Securities from such transferring Investor (or, if less, all
      Registrable Securities then held by such transferring Investor), (b) to a
      transferee or assignee who holds Registrable Securities immediately prior to
      such transfer or assignment, (c) in the case of an
      Investor that is an investment fund, to an investment fund under common
      management with such Investor, (d) in the case of an Investor that is a
      partnership or limited liability company, to any partners or members of such
      partnership or limited liability company, (e) in the case of an Investor that
      is
      a corporation, to any stockholders of such corporation, and (f) in the case
      of
      an Investor that is a trust, to any beneficiaries of such trust.;
      provided that in the case of (a), (i) prior to such transfer or assignment,
      the
      Company is furnished with written notice stating the name and address of such
      transferee or assignee and identifying the securities with respect to which
      such
      registration rights are being transferred or assigned, (ii) such transferee
      or
      assignee agrees in writing to be bound by and subject to the terms and
      conditions of this Agreement, including without limitation the provisions of
      Section 1.9 and (iii) such transfer or assignment shall be effective only if
      immediately following such transfer or assignment the further disposition of
      such securities by the transferee or assignee is restricted under the Securities
      Act. 

     

    
      
        
        

      

      
        7

        
          

        

      

       

    

     

    1.9  “MARKET
      STAND-OFF” AGREEMENT. Each Investor hereby agrees, subject to its rights under
      Section 2.3 below, that it will not, without the prior written consent of the
      managing underwriter, during the period commencing on the date of the final
      prospectus relating to the Company’s initial underwritten public offering and
      ending on the date specified by the Company and the managing underwriter (such
      period not to exceed one hundred eighty (180) calendar days) (i) lend, offer,
      pledge, sell, contract to sell, sell any option or contract to purchase,
      purchase any option or contract to sell, grant any option, right or warrant
      to
      purchase, or otherwise transfer or dispose of, directly or indirectly, any
      securities of the Company, including (without limitation) shares of Common
      Stock
      or any securities convertible into or exercisable or exchangeable for Common
      Stock (whether now owned or hereafter acquired) or (ii) enter into any swap
      or
      other arrangement that transfers to another, in whole or in part, any of the
      economic consequences of ownership of any securities of the Company, including
      (without limitation) shares of Common Stock or any securities convertible into
      or exercisable or exchangeable for Common Stock (whether now owned or hereafter
      acquired), whether any such transaction described in clause (i) or (ii) above
      is
      to be settled by delivery of securities, in cash or otherwise. The foregoing
      covenants shall apply only to the Company’s initial underwritten public offering
      of equity securities, shall not apply to the sale of any shares by an Investor
      to an underwriter pursuant to an underwriting agreement and shall only be
      applicable to the Investors if all the Company’s executive officers, directors
      and greater than five percent (5%) stockholders enter into similar agreements.
      Each Investor agrees to execute an agreement(s) reflecting (i) and (ii) above
      as
      may be requested by the managing underwriters at the time of the initial
      underwritten public offering, and further agrees that the Company may impose
      stop transfer instructions with its transfer agent in order to enforce the
      covenants in (i) and (ii) above. The underwriters in connection with the
      Company’s initial underwritten public offering are intended third party
      beneficiaries of the covenants in this Section 1.9 and shall have the right,
      power and authority to enforce such covenants as though they were a party
      hereto. 

     

    
      
        
        

      

      
        8

        
          

        

      

       

    

     

    2.  COVENANTS
      OF THE COMPANY TO THE INVESTORS. 

     

    2.1  INFORMATION
      RIGHTS. The Company shall deliver to each Investor who holds (and continues
      to
      hold) at least 50,000 shares of Registrable Securities (subject to appropriate
      adjustment for stock splits, stock dividends and combinations), upon the request
      of such Investor (which may be satisfied by filing of Company quarterly and
      annual reports under the Exchange Act): 

     

    (a) as
      soon
      as practicable, but in any event within one hundred twenty (120) calendar days
      after the end of each fiscal year of the Company, consolidated balance sheets
      of
      the Company and its subsidiaries, if any, as of the end of such fiscal year,
      and
      consolidated statements of income and consolidated statements of cash flows
      of
      the Company and its subsidiaries, if any, for such year, prepared in accordance
      with generally accepted accounting principles (“GAAP”), all in reasonable
      detail; and 

    

    (b) as
      soon
      as practicable, but in any event within forty-five (45) calendar days after
      the
      end of each of the first three (3) quarters of each fiscal year of the Company,
      consolidated balance sheets of the Company and its subsidiaries, if any, as
      of
      the end of such quarter, and consolidated statements of income and consolidated
      statements of cash flows of the Company and its subsidiaries, if any, for such
      quarter prepared in accordance with GAAP, all in reasonable detail.

    

    2.2  CONFIDENTIALITY.
      Each Investor receiving any non-public information of the Company hereby agrees
      to hold in confidence and trust and to act in a fiduciary manner with respect
      to
      all information so provided; PROVIDED, HOWEVER, that notwithstanding the
      foregoing, an Investor may include summary financial information concerning
      the
      Company and general statements concerning the nature and progress of the
      Company’s business in an Investor’s reports to its affiliates

     

    2.3  OTHER
      REGISTRATION RIGHTS. Except for the shares of Common Stock to be registered
      pursuant to the Company’s Registration Rights Agreement dated January 5, 2006
      (the “Existing
      Registration Rights Agreement”),
      neither the Company nor any of its other security holders may include securities
      of the Company in the Registration Statement (other than the Shares and
      Conversion Shares and shares of Common Stock and shares of Common Stock issuable
      upon the exercise of warrants issued in the Additional Financing) without the
      consent of a majority in interest of the Investors. The Company shall not file
      any other registration statements with the Commission until the Registration
      Statement required hereunder is declared effective by the Commission, except
      registration statements on Form S-8 solely covering employee stock benefits.
      No
      other person shall be granted the right to cause the Company to effect the
      registration under the Securities Act of any securities of the Company prior
      to
      filing the Registration Statement, nor shall the Company effect any amendment,
      modification or waiver of any provision of the Existing Registration Rights
      Agreement in any manner that would adversely affect the rights of the Investors
      hereunder .

     

    
      
        
        

      

      
        9

        
          

        

      

       

    

     

    3.  LEGEND.
      

     

    (a) Each
      certificate representing the shares of Common Stock held by the Investors shall
      be endorsed with the following legend (the “LEGEND”): 

    

    THE
      SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD OF UP
      TO
      180 DAYS FOLLOWING THE EFFECTIVE DATE OF A REGISTRATION STATEMENT OF THE COMPANY
      FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AS SET FORTH IN THAT CERTAIN
      REGISTRATION RIGHTS AGREEMENT BETWEEN THE CORPORATION AND THE ORIGINAL HOLDER
      OF
      THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE CORPORATION’S PRINCIPAL
      OFFICE. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE SHARES.

    

    (b) The
      Company agrees that, during the term of this Agreement, it will not remove,
      and
      will not permit to be removed (upon registration of transfer, re-issuance or
      otherwise), the Legend from any such certificate and will place or cause to
      be
      placed the Legend on any new certificate theretofore represented by a
      certificate carrying the Legend. 

    

    4.  MISCELLANEOUS.
      

     

    4.1  GOVERNING
      LAW. This Agreement shall be governed in all respects by the laws of the State
      of New York as such laws are applied to agreements between New York residents
      entered into and to be performed entirely within New York, without regard to
      conflict of laws rules. 

     

    4.2  WAIVERS
      AND AMENDMENTS. This Agreement may be terminated and any term of this Agreement
      may be amended or waived (either generally or in a particular instance and
      either retroactively or prospectively) with the written consent of the Company
      and Investors holding at least a majority of the Registrable Securities then
      outstanding (the “MAJORITY INVESTORS”). Notwithstanding the foregoing,
      additional parties may be added as Investors under this Agreement with the
      written consent of the Company and the Majority Investors. No such amendment
      or
      waiver shall reduce the aforesaid percentage of the Registrable Securities,
      the
      holders of which are required to consent to any termination, amendment or waiver
      without the consent of the record holders of all of the Registrable Securities.
      Any termination, amendment or waiver effected in accordance with this Section
      4.2 shall be binding upon each holder of Registrable Securities then
      outstanding, each future holder of all such Registrable Securities and the
      Company. 

     

    4.3  SUCCESSORS
      AND ASSIGNS. Except as otherwise expressly provided herein, the provisions
      of
      this Agreement shall inure to the benefit of, and be binding upon, the
      successors, assigns, heirs, executors and administrators of the parties hereto.
      

     

    4.4  ENTIRE
      AGREEMENT. This Agreement constitutes the full and entire understanding and
      agreement among the parties with regard to the subject matter hereof, and no
      party shall be liable or bound to any other party in any manner by any
      warranties, representations or covenants except as specifically set forth
      herein. 

     

    
      
        
        

      

      
        10

        
          

        

      

       

    

     

    4.5  NOTICES.
      All notices and other communications required or permitted under this Agreement
      shall be in writing and shall be delivered personally by hand or by courier,
      mailed by United States first-class mail, postage prepaid, sent by facsimile
      or
      sent by electronic mail directed (a) if to an Investor, at such Investor’s
      address, facsimile number or electronic mail address set forth in the Company’s
      records, or at such other address, facsimile number or electronic mail address
      as such Investor may designate by ten (10) days’ advance written notice to the
      other parties hereto or (b) if to the Company, to its address, facsimile number
      or electronic mail address set forth on its signature page to this Agreement
      and
      directed to the attention of the President, or at such other address, facsimile
      number or electronic mail address as the Company may designate by ten (10)
      days’
advance written notice to the other parties hereto. All such notices and other
      communications shall be effective or deemed given upon personal delivery, on
      the
      date of mailing, upon confirmation of facsimile transfer or upon confirmation
      of
      electronic mail delivery. 

     

    4.6  INTERPRETATION.
      The words “include,” “includes” and “including” when used herein shall be deemed
      in each case to be followed by the words “without limitation.” The titles and
      subtitles used in this Agreement are used for convenience only and are not
      considered in construing or interpreting this Agreement. 

     

    4.7  SEVERABILITY.
      If one or more provisions of this Agreement are held to be unenforceable under
      applicable law, such provision shall be excluded from this Agreement, and the
      balance of the Agreement shall be interpreted as if such provision were so
      excluded, and shall be enforceable in accordance with its terms. 

     

    4.8  COUNTERPARTS.
      This Agreement may be executed in any number of counterparts, each of which
      shall be an original, but all of which together shall constitute one instrument.
      

     

    4.9  TELECOPY
      EXECUTION AND DELIVERY. A facsimile, telecopy or other reproduction of this
      Agreement may be executed by one or more parties hereto, and an executed copy
      of
      this Agreement may be delivered by one or more parties hereto by facsimile
      or
      similar electronic transmission device pursuant to which the signature of or
      on
      behalf of such party can be seen, and such execution and delivery shall be
      considered valid, binding and effective for all purposes. At the request of
      any
      party hereto, all parties hereto agree to execute an original of this Agreement
      as well as any facsimile, telecopy or other reproduction hereof. 

     

    4.10  WARRANT
      EXERCISE. Any warrant exercised pursuant to which Common Stock may be issued
      subject to the registration rights herein shall constitute restricted Common
      Stock. 

    
      
        
        

      

      
        11

        
          

        

      

       

    

    IN
      WITNESS WHEREOF, the parties have executed this Agreement on the day, month
      and
      year first set forth above. 

    
      	 	 	 
	 	
              “Company”
                

               

              NEURO-HITECH,
                INC.

            
	 
 	 
 	 
 
	
            	By:  	/s/
              David Barrett
	 	
              
                

              

              Name:
                David Barrett

              Title:
                Chief Financial Officer 

            
	 	 
	 	
              ADDRESS:

              
                

                Neuro-Hitech,
                  Inc.

                One
                  Penn Plaza, Suite 1503

                New
                  York, New York 10119

                Telephone:
                  (212) ____________

                Telecopy:
                  (212) ___________

                Email:____________________

                Attention:
                  Chief Executive Officer 

              

            

      	 	 	 
	 	
              
                “Investors”
                  

                 

                WHEATLEY
                  MEDTECH PARTNERS, LP 

              

            
	 
 	 
 	 
 
	
            	By:  	/s/
              Barry Rubenstein  
	 	
              
                

              

              Name:
                Barry Rubenstein

              Title:
                CEO, Wheatley MedTech Parnters, LLC, General
                Partner

            
	 	 
	 	
              
                ADDRESS:

                

                ___________________________________

                ___________________________________

                ___________________________________

                Telephone:__________________________

                Telecopy:___________________________

                Email:______________________________

              

            

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    
      	 	 	 
	 	
              
                
                  WHEATLEY
                    NEW YORK PARTNERS, LP 

                

              

            
	 
 	 
 	 
 
	
            	By:  	/s/
              Barry Rubenstein  
	 	
              
                

              

              Name:
                Barry Rubenstein

              Title:
                CEO, Wheatley MedTech Parnters, LLC, General
                Partner

            
	 	 
	 	
              
                ADDRESS:

                

                ___________________________________

                ___________________________________

                ___________________________________

                Telephone:__________________________

                Telecopy:___________________________

                Email:______________________________

              

            

    

    

    
      	 	 	 
	 	
              
                
                  
                    DURAND
                      VENTURES 

                  

                

              

            
	 
 	 
 	 
 
	
            	By:  	/s/
              Douglas N.
              Durand
	 	
              
                

              

              Name:
                Douglas N. Durand

              Title:
                Managing Director

            
	 	 
	 	
              
                ADDRESS:

                

                ___________________________________

                ___________________________________

                ___________________________________

                Telephone:__________________________

                Telecopy:___________________________

                Email:______________________________

              

            

      	 	 	 
	 	
              
                
                  
                    
                      Heller
                        Capital Investments,
                        LLC

                    

                  

                

              

            
	 
 	 
 	 
 
	
            	By:  	/s/
              Ronald I.
              Heller   
	 	
              
                

              

              Name:
                Ronald I. Heller

              Title:
                CIO

              Address:

            

    

    
      	 	 	 
	 	 	 
	 	
              
                
                  
                    
                      
                        CGM
                          as C/F Ronald I. Heller
                          (IRA)

                      

                    

                  

                

              

            
	 
 	 
 	 
 
	
            	By:  	/s/
              Ronald I.
              Heller   
	 	
              
                

              

              Name:
                Ronald I. Heller

              Address:

            

    

    
      
        
        

      

      
        13

        
          

        

      

       

    

    
      	 	 	 
	 	
              
                
                  
                    
                      
                        
                          CGM
                            as C/F David S. Nagelberg
                            (IRA)

                        

                      

                    

                  

                

              

            
	 
 	 
 	 
 
	
            	By:  	/s/
              David S.
              Nagelberg  
	 	
              
                

              

              Name:
                David S. Nagelberg

              Address:

            

    

    

    
      
        
        

      

      
        14THIS
      WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT
      BEEN
      REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER
      THE SECURITIES LAWS OF ANY APPLICABLE STATES. THESE SECURITIES ARE SUBJECT
      TO
      RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD
      EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS,
      PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE
      THAT
      THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN
      INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION
      OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT
      ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT AND ANY APPLICABLE
      STATE SECURITIES LAWS.

     

    WARRANT
      TO PURCHASE COMMON STOCK

    OF

    NEURO-HITECH,
      INC.

     

    
      	Warrant No. _____ 	
              Issued
                on November 29, 2006

            
	 	
              Void
                after November 29, 2016

            

    

     

    This
      certifies that in connection with the Merger Agreement (as defined below),
      _______ is entitled, subject to the terms and conditions of this Warrant, to
      purchase from Neuro-Hitech, Inc., a Delaware corporation (the “Company”),
      at
      any time prior to November 29, 2016 (the “Expiration
      Date”)
      up to
      _________ shares of the Company’s Common Stock, $0.001 par value per share (the
“Common
      Stock”) at
      a
      price per share equal to the Warrant Price (as defined below), upon surrender
      of
      this Warrant at the principal offices of the Company, together with a duly
      executed subscription form in the form attached hereto as Exhibit
      1
      and
      simultaneous payment of the full Warrant Price for the shares of Common Stock
      so
      purchased in lawful money of the United States, or as otherwise provided herein.
      The Warrant Price and the number and character of shares of Common Stock
      purchasable under this Warrant are subject to adjustment as provided
      herein.

     

    This
      Warrant is issued pursuant to the Agreement and Plan of Merger Agreement, dated
      of even date herewith, by and among the Company, QA Acquisition Corp., a
      Delaware corporation, QA Merger LLC, a Delaware limited liability company,
      Q-RNA, Inc., a Delaware corporation and Dr. David Dantzker, as “Representative”
of the Stockholders (the “Merger
      Agreement”),
      and
      is subject to the indemnity provisions set forth in Section 9 of the Merger
      Agreement, which provide for the automatic adjustment of the number of shares
      of
      Common Stock subject to this Warrant in certain circumstances.

     

    1.  DEFINITIONS.
      Capitalized terms used in this Warrant and not otherwise defined herein shall
      have the meanings given to them in the Merger Agreement. The following
      definitions shall apply for purposes of this Warrant:

     

    1.1  “Company”
means
      the “Company”
as
      defined above and includes any corporation which shall succeed to or assume
      the
      obligations of the Company under this Warrant.

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    1.2  “Corporate
      Transaction”
shall
      mean (i) an acquisition of the Company by another entity (the “Successor
      Entity”) by means of merger, consolidation or stock sale resulting in the
      disposition of the Common Stock for securities or other consideration issued,
      or
      caused to be issued, by the Successor Entity in which the holders of the Common
      Stock then hold, directly or indirectly, less than fifty percent (50%) of the
      voting securities of the Successor Entity or (ii) a sale by the Company of
      all
      or substantially all of its assets to the Successor Entity in which the holders
      of the Common Stock then hold, directly or indirectly, less than fifty percent
      (50%) of the voting securities of the Successor Entity.

     

    1.3  “Fair
      Market Value”
on
      any
      day shall mean (a) if shares of Common Stock are listed or admitted for trading
      on a national securities exchange, the reported last sales price or, if no
      such
      reported sale occurs on such day, the average of the closing bid and asked
      prices on such day, in each case on the principal national securities exchange
      on which the Common Stock are listed or admitted to trading, (b) if shares
      of
      Common Stock are not listed or admitted to trading on any national securities
      exchange, the average of the closing bid and asked prices in the
      over-the-counter market on such day as reported by Nasdaq or any comparable
      system or, if not so reported, as reported by any New York Stock Exchange member
      firm selected by the Company for such purpose or (c) if no such quotations
      are
      available on such day, the fair market value of one share of Common Stock on
      such day as determined in good faith by the Board of Directors of the
      Company.

     

    1.4  “Holder”
means
      any person who shall at the time be the registered holder of this
      Warrant.

     

    1.5  “Warrant”
means
      this Warrant and any warrant(s) delivered in substitution or exchange therefor,
      as provided herein.

     

    1.6  “Warrant
      Price”
means
      $13.00 per share. The Warrant Price is subject to adjustment as provided
      herein.

     

    2.  EXERCISE.

     

    2.1  Timing
      and Method of Exercise.
      

     

    (a)  Method
      of Exercise.
      Subject
      to the terms and conditions of this Warrant, the Holder may exercise this
      Warrant on any business day before the Expiration Date for up to _______________
      shares of Common Stock, by surrendering this Warrant at the principal offices
      of
      the Company, with the subscription form attached hereto duly executed by the
      Holder, and payment of an amount equal to the product obtained by multiplying
      (i) the number of shares of Common Stock to be purchased by the Holder by
      (ii) the Warrant Price or adjusted Warrant Price therefor, if applicable,
      as determined in accordance with the terms hereof.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    (b)  Cashless
      Exercise.
      In lieu
      of exercising this Warrant as hereinabove permitted, immediately prior to the
      closing of a Corporate Transaction the Holder may elect to exercise this Warrant
      or a portion hereof and to pay for the Common Stock issuable upon such exercise
      by way of cashless exercise by surrendering this Warrant at the principal
      executive office of the Company, together with the subscription form attached
      hereto electing cashless exercise, in which event the Company shall, immediately
      prior to such closing, issue to the Holder that number of shares of Common
      Stock
      computed using the following formula:

     

    
      	
              X=
                Y
                x (A-B)

            
	
              A

            

    

     

    Where:

     

    X
      equals
      the number of shares of Common Stock to be issued to the Holder;

     

    Y
      equals
      the number of shares of Common Stock purchasable under the Warrant, or, if
      only
      a portion of the Warrant is being exercised, the portion of the Warrant being
      exercised at the date of such calculation;

     

    A
      equals
      the Fair Market Value (at the date of such calculation) of one share of Common
      Stock; and

     

    B
      equals
      the Warrant Price.

     

    2.2  Form
      of Payment.
      Except
      as otherwise provided in Section 2.1(b) above, payment may be made by (i) a
      check payable to the Company’s order, (ii) wire transfer of funds to the
      Company, or (iii) any combination of the foregoing.

     

    2.3  No
      Fractional Shares.
      No
      fractional shares may be issued upon any exercise of this Warrant, and any
      fractions shall be rounded down to the nearest whole number of shares. If upon
      any exercise of this Warrant a fraction of a share results, the Company will
      pay
      the cash value of any such fractional share, calculated on the basis of the
      difference between the Fair Market Value and the Warrant Price.

     

    2.4  Restrictions
      on Exercise.
      This
      Warrant may not be exercised if the issuance of the Warrant Stock upon such
      exercise would constitute a violation of any applicable federal or state
      securities laws or other laws or regulations. As a condition to the exercise
      of
      this Warrant, the Holder shall execute the subscription form attached hereto
      as
Exhibit 1,
      confirming and acknowledging that the representations and warranties made by
      the
      Holder in the “accredited investor” questionnaire described in Section 7.15 of
      the Merger Agreement are true and correct as of the date of
      exercise.

     

    3.  ISSUANCE
      OF STOCK.
      This
      Warrant shall be deemed to have been exercised immediately prior to the close
      of
      business on the date of its surrender for exercise as provided above, and the
      person entitled to receive the shares of Common Stock issuable upon such
      exercise shall be treated for all purposes as the holder of record of such
      shares as of the close of business on such date. As soon as practicable on
      or
      after such date, the Company shall issue and deliver to the person or persons
      entitled to receive the same a certificate or certificates for the number of
      whole shares of Warrant Stock issuable upon such exercise.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    4.  ADJUSTMENT
      PROVISIONS.
      The
      number and character of shares of Common Stock issuable upon exercise of this
      Warrant (or any shares of stock or other securities or property at the time
      receivable or issuable upon exercise of this Warrant) and the Warrant Price
      therefor, are subject to adjustment pursuant to the terms of the indemnity
      provisions of the Merger Agreement and upon the occurrence of the following
      events between the date this Warrant is issued and the date it is
      exercised:

     

    4.1  Adjustment
      for Stock Splits and Stock Dividends.
      The
      Warrant Price of this Warrant and the number of shares of Warrant Stock issuable
      upon exercise of this Warrant (or any shares of stock or other securities at
      the
      time issuable upon exercise of this Warrant) shall each be proportionally
      adjusted to reflect any stock dividend, stock split or reverse stock split,
      or
      other similar event affecting the number of outstanding shares of Common Stock
      (or such other stock or securities). 

     

    4.2  Adjustment
      for Other Dividends and Distributions.
      In case
      the Company shall make or issue, or shall fix a record date for the
      determination of eligible holders entitled to receive, a dividend or other
      distribution payable respect to the Common Stock that is payable in
      (a) securities of the Company (other than issuances with respect to which
      adjustment is made under Sections 4.1 or 4.3) or (b) assets (other
      than cash dividends paid or payable solely out of retained earnings), then,
      and
      in each such case, the Holder, upon exercise of this Warrant at any time after
      the consummation, effective date or record date of such event, shall receive,
      in
      addition to the shares of Common Stock issuable upon such exercise prior to
      such
      date, the securities or such other assets of the Company to which the Holder
      would have been entitled upon such date if the Holder had exercised this Warrant
      immediately prior thereto (all subject to further adjustment as provided in
      this
      Warrant).

     

    4.3  Adjustment
      for Reorganization, Consolidation, Merger.
      In case
      of any recapitalization or reorganization of the Company after the date of
      this
      Warrant, or in case, after such date, the Company shall consolidate with or
      merge into another corporation, then, and in each such case, the Holder, upon
      the exercise of this Warrant (as provided in Section 2), at any time after
      the consummation of such recapitalization, reorganization, consolidation or
      merger, shall be entitled to receive, in lieu of the stock or other securities
      and property receivable upon the exercise of this Warrant prior to such
      consummation, the stock or other securities or property to which the Holder
      would have been entitled upon the consummation of such recapitalization,
      reorganization, consolidation or merger if the Holder had exercised this Warrant
      immediately prior thereto, all subject to further adjustment as provided in
      this
      Warrant, and the successor or purchasing corporation in such reorganization,
      consolidation or merger (if other than the Company) shall duly execute and
      deliver to the Holder a supplement hereto acknowledging such corporation’s
      obligations under this Warrant; and in each such case, the terms of this Warrant
      shall be applicable to the shares of stock or other securities or property
      receivable upon the exercise of this Warrant after the consummation of such
      reorganization, consolidation or merger.

     

    4.4  Conversion
      of Stock.
      In case
      all the authorized Common Stock of the Company is converted, pursuant to the
      Company’s certificate of incorporation, into other securities or property of the
      Company, or the Common Stock otherwise ceases to exist, then, in such case,
      the
      Holder, upon exercise of this Warrant at any time after the date on which the
      Common Stock is so converted or ceases to exist (the “Termination
      Date”),
      shall
      receive, in lieu of the number of shares of Common Stock that would have been
      issuable upon such exercise immediately prior to the Termination Date (the
      “Former
      Number of Shares of Common Stock”),
      the
      stock and other securities and property which the Holder would have been
      entitled to receive upon the Termination Date if the Holder had exercised this
      Warrant with respect to the Former Number of Shares of Common Stock immediately
      prior to the Termination Date (all subject to further adjustment as provided
      in
      this Warrant).

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    4.5  Notice
      of Adjustments.
      The
      Company shall promptly give written notice of each adjustment or readjustment
      of
      the Warrant Price or the number of shares of Common Stock or other securities
      issuable upon exercise of this Warrant. The notice shall describe the adjustment
      or readjustment and show in reasonable detail the facts on which the adjustment
      or readjustment is based.

     

    4.6  No
      Change Necessary.
      The
      form of this Warrant need not be changed because of any adjustment in the
      Warrant Price or in the number of shares of Common Stock issuable upon its
      exercise.

     

    4.7  Reservation
      of Stock.
      The
      Company shall at all times reserve and keep available, solely for the issuance
      and delivery upon the exercise of this Warrant, such shares of Common Stock
      and
      other stock, securities and property, as from time to time shall be issuable
      upon the exercise of this Warrant. If
      at any
      time the number of shares of Common Stock or other securities issuable upon
      exercise of this Warrant shall not be sufficient to effect the exercise of
      this
      Warrant, the Company will take such corporate action as may, in the opinion
      of
      its counsel, be necessary to increase its authorized but unissued shares of
      Common Stock or other securities issuable upon exercise of this Warrant as
      shall
      be sufficient for such purpose. All
      shares of Common Stock issued upon exercise of the Warrant shall be validly
      issued, fully paid and nonassessable.

     

    5.  NO
      RIGHTS OR LIABILITIES AS STOCKHOLDER.
      This
      Warrant does not by itself entitle the Holder to any voting rights or other
      rights as a stockholder of the Company. In the absence of affirmative action
      by
      the Holder to purchase Common Stock by exercise of this Warrant, no provisions
      of this Warrant, and no enumeration herein of the rights or privileges of the
      Holder, shall cause the Holder to be a stockholder of the Company for any
      purpose.

     

    6.  NO
      IMPAIRMENT.
      The
      Company will not, by amendment of its certificate of incorporation or bylaws,
      or
      through reorganization, consolidation, merger, dissolution, issue or sale of
      securities, sale of assets or any other voluntary action, willfully avoid or
      seek to avoid the observance or performance of any of the terms of this Warrant,
      but will at all times in good faith assist in the carrying out of all such
      terms
      and in the taking of all such action as may be necessary or appropriate in
      order
      to protect the rights of the holder against wrongful impairment. Without
      limiting the generality of the foregoing, the Company will take all such action
      as may be necessary or appropriate in order that the Company may duly and
      validly issue fully paid and nonassessable shares of Common Stock upon the
      exercise of this Warrant.

     

    7.  TRANSFER.
      Neither
      this Warrant nor any rights hereunder may be assigned, conveyed or transferred,
      in whole or in part, without the Company’s prior written consent, which the
      Company may withhold in its sole discretion. The rights and obligations of
      the
      Company and the Holder under this Warrant and the Merger Agreement shall be
      binding upon and benefit their respective permitted successors, assigns, heirs,
      administrators and transferees.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    8.  GOVERNING
      LAW.
      The
      internal laws of the State of Delaware (irrespective of its choice of law
      principles) will govern the validity of this Warrant, the construction of its
      terms, and the interpretation and enforcement of the rights and duties of the
      parties hereto.

     

    9.  HEADINGS.
      The
      headings and captions used in this Warrant are used only for convenience and
      are
      not to be considered in construing or interpreting this Warrant. All references
      in this Warrant to sections and exhibits shall, unless otherwise provided,
      refer
      to sections hereof and exhibits attached hereto, all of which exhibits are
      incorporated herein by this reference.

     

    10.  NOTICES.
      Any
      notice or other communication required or permitted to be given under this
      Warrant will be in writing, will be delivered personally or by registered or
      certified mail, postage prepaid and will be deemed given upon delivery, if
      delivered personally, or three days after deposit in the mails, if mailed,
      to
      the address indicated for the Holder on the signature page to this Warrant,
      or
      in the case of the Company, at One Penn Plaza, Suite 2514, New York, NY 10119,
      Attn: Chief Financial Officer, or at such other address as any party or the
      Company may designate by giving ten (10) days’ advance written notice to all
      other parties

     

    11.  AMENDMENT;
      WAIVER.
      This
      Warrant and all other Warrants issued under the Merger Agreement may be amended
      and provisions may be waived by the Company and the warrant holders of at least
      a majority of the Common Stock underlying the Warrants. Any
      amendment or waiver effected in accordance with this Section shall be binding
      upon the
      Holder and
      each
      future holder of such securities, and the Company.

     

    12.  SEVERABILITY.
      If any
      provision of this Warrant, or the application thereof, will for any reason
      and
      to any extent be invalid or unenforceable, the remainder of this Warrant and
      application of such provision to other persons or circumstances will be
      interpreted so as reasonably to effect the intent of the parties hereto. The
      parties further agree to replace such void or unenforceable provision of this
      Agreement with a valid and enforceable provision that will achieve, to the
      extent possible, the economic, business and other purposes of the void or
      unenforceable provision.

     

    13.  TERMS
      BINDING.
      By
      acceptance of this Warrant, the Holder accepts and agrees to be bound by all
      the
      terms and conditions of this Warrant.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    IN
      WITNESS WHEREOF, the
      parties hereto have executed this Warrant as of the date first above
      written.

     

    
      THE
        COMPANY:

    

     

    
      	
              NEURO-HITECH,
                INC.

            	 
	 	 	 
	
              By:

            	 	 
	 	 	 
	
              Name:

            	
              David
                Barrett

            	 
	 	 	 
	
              Title:

            	
              Chief
                Financial Officer

            	 

    

    
      
        
        

      

      
        
        

        
          

        

      

       

    

    EXHIBIT 1

     

    FORM
      OF SUBSCRIPTION

    (To
      be signed only upon exercise of Warrant)

     

    To:
      Neuro-Hitech, Inc.

     

    (1)  The
      undersigned Holder hereby elects to purchase     
        
      shares
      of Common Stock of Neuro-Hitech, Inc. (the “Warrant
      Stock”),
      pursuant to the terms of the attached Warrant, and:

     

    _______
      tenders herewith payment of the purchase price for such shares in full;
      or

     

    _______
      elects cashless exercise pursuant to Section 2.1(b) of the attached
      Warrant.

     

    (Please
      check one)

     

    (2)  In
      exercising the Warrant, the undersigned Holder hereby confirms and acknowledges
      that the representations made by the Holder in the “accredited investor”
questionnaire described in Section 7.15 of the Merger Agreement (as defined
      in
      the Warrant) continue to be true and correct as of this date. 

     

    (3)  Please
      issue a certificate or certificates representing such shares of Warrant Stock
      in
      the name specified below:

     

    
      	 
	 
	
              (Name)

            
	 
	 
	
              (Address)

            
	 
	 
	
              (City,
                State, Zip Code)

            
	 
	 
	
              (Federal
                Tax Identification Number)

            
	 
	 
	
              (Date)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]